Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company focusing on precision oncology through synthetic lethality, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company focusing on precision oncology through synthetic lethality, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY.
Dr. Oren Gilad, President and CEO of Aprea, will deliver a corporate update during the conference. The presentation will be available on-demand starting at 7:00 A.M. (ET) on September 9, 2024, and will remain accessible for 90 days. Interested parties can access the webcast through the provided link.
Additionally, Aprea's management team will be available for one-on-one meetings with institutional investors during the conference. Attendees interested in scheduling a meeting are advised to contact their conference representative.
Details
News Market Reaction – APRE
The recorded move for APRE in the trading session of this news was -0.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York, NY. Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference
| Date: | September 9-11, 2024 |
| Location: | New York, NY |
| Webcast: | click here |
The above presentation is available to access “on-demand”, beginning at 7:00 A.M. (ET), on September 9, 2024. It will be available for 90 days.
Management will be available for one-on-one meetings with institutional investors. To request a meeting, please contact your conference representative.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.